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Background: The World Health Organization recommends parasitological confirmation of all malaria cases.
Tanzania is implementing a phased rollout of malaria rapid diagnostic tests (RDTs) for routine use in all levels of
care as one strategy to increase parasitological confirmation of malaria diagnosis. This study was carried out to
evaluated artemisinin combination therapy (ACT) prescribing patterns in febrile patients with and without
uncomplicated malaria in one pre-RDT implementation and one post-RDT implementation area.
Methods: A cross-sectional health facility surveys was conducted during high and low malaria transmission seasons
in 2010 in both areas. Clinical information and a reference blood film on all patients presenting for an initial illness
consultation were collected. Malaria was defined as a history of fever in the past 48 h and microscopically
confirmed parasitaemia. Routine diagnostic testing was defined as RDT or microscopy ordered by the health worker
and performed at the health facility as part of the health worker-patient consultation. Correct diagnostic testing was
defined as febrile patient tested with RDT or microscopy. Over-testing was defined as a non-febrile patient tested
with RDT or microscopy. Correct treatment was defined as patient with malaria prescribed ACT. Over-treatment was
defined as patient without malaria prescribed ACT.
Results: A total of 1,247 febrile patients (627 from pre-implementation area and 620 from post-implementation
area) were included in the analysis. In the post-RDT implementation area, 80.9% (95% CI, 68.2-89.3) of patients with
malaria received recommended treatment with ACT compared to 70.3% (95% CI, 54.7-82.2) of patients in the
pre-RDT implementation area. Correct treatment was significantly higher in the post-implementation area during
high transmission season (85.9% (95%CI, 72.0-93.6) compared to 58.3% (95%CI, 39.4-75.1) in pre-implementation
area (p = 0.01). Over-treatment with ACT of patients without malaria was less common in the post-RDT
implementation area (20.9%; 95% CI, 14.7-28.8) compared to the pre-RDT implementation area (45.8%; 95% CI,
37.2-54.6) (p < 0.01) in high transmission. The odds of overtreatment was significantly lower in post- RDT area (adjusted
Odds Ratio (OR: 95%CI) 0.57(0.36-0.89); and much higher with clinical diagnosis adjusted OR (95%CI) 2.24(1.37-3.67)
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Conclusion: Implementation of RDTs increased use of RDTs for parasitological confirmation and reduced over-treatment
with ACT during high malaria transmission season in one area in Tanzania. Continued monitoring of the national RDT
rollout will be needed to assess whether these changes in case management practices will be replicated in other areas
and sustained over time. Additional measures (such as refresher trainings, closer supervisions, etc.) may be needed to
improve ACT targeting during low transmission seasons.
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The World Health Organization (WHO) recommends
that clinically suspected malaria be confirmed parasito-
logically prior to treatment [1]. Diagnosis based on signs
and symptoms has varied sensitivity and specificity de-
pending on clinical features present, age, and
transmission-associated acquired immunity [2]. Micro-
scopic analysis of blood films for malaria parasites has been
the most commonly used method for parasitological con-
firmation of malaria infection. However, due to reports of
poor quality malaria microscopy [3,4] and the logistical,
personnel and financial resources required to increase
coverage of quality microscopy services, many endemic
countries in sub-Saharan Africa have opted to use malaria
rapid diagnostic tests (RDTs) to expand the use of
parasitological-based malaria diagnosis [5,6].
Tanzania mainland introduced the use of artemether-
lumefantrine (AL), an artemisinin-based combination
therapy (ACT), as a first line treatment for uncompli-
cated malaria in 2006 [7]. In early 2009, a phased rollout
of RDTs was initiated in all levels of care to complement
microscopy services for parasitological confirmation of
malaria prior to treatment (National guideline for the
use of rapid malaria diagnostic tests in Tanzania, 2007,
National Malaria Control Programme, Dar es Salaam,
Tanzania: unpublished). This roll-out is expected to
cover the entire country before end of year 2012. Since
the adoption of RDT policy and increased rollout of this
strategy in sub-Saharan Africa, there has been limited
evidence of the performance of RDTs in routine use and
their impact on case management practices, on a wider
scale, outside research settings.
Using a pair of cross-sectional health facility surveys
conducted in two areas of Tanzania in 2010, this study
assessed the impact of RDTs by comparing malaria case
management practices in a post-RDT implementation
area with a pre-RDT implementation area. The assess-
ment aimed on determining ACT targeting accuracy, i.e.
the proportion of patients presenting to ACT provider
for initial illness consultation with fever or history of
fever in the last 48 h who were prescribed AL; and pro-
vider compliance, i.e. the proportion of patients present-
ing to an ACT provider for initial illness consultation
with fever or history of fever in the last 48 h and bloodslide confirmed malaria parasitaemia, who were pre-
scribed AL.
In the post-RDT implementation area, Rufiji Health
and Demographic Surveillance System (HDSS) located
in Rufiji District, RDTs were introduced for routine use
in November 2009 as part of the national rollout. In the
pre-RDT implementation area, Ifakara HDSS located in
Kilombero and Ulanga Districts, RDT were not intro-
duced as part of the national roll-out, but were available
in seven health facilities (out of 79 health facilities in
Kilombero and Ulanga districts) as part of small scale re-
search study; the ACCESS programme, since 2008 [8].
Methods
INDEPTH Network Effectiveness and Safety Studies of
Antimalarial Drugs in Africa platform (INESS) operates
in HDSSs in Rufiji District, Coast Region, and in Kilo-
mbero and Ulanga Districts, around the town of Ifakara,
Morogoro Region, Tanzania [9]. The platform assesses
safety and community effectiveness of anti-malarial
drugs in real life health systems. As part of this effort,
INESS conducts assessments of the quality of malaria
case management using a series of health facility surveys
to evaluate ACT prescribing patterns among febrile
patients with and without parasitological confirmed un-
complicated malaria.
Study area
The study was conducted in health facilities located in
the Rufiji and Ifakara HDSS areas, in March and Octo-
ber 2010 corresponding to high and low malaria trans-
mission seasons respectively at those sites. The Rufiji
HDSS has been operational since 1998 and contains a
population of approximately 85,000 people [10]. Malaria
rapid tests were available on a limited scale as part of
demonstration project in 12 health facilities in the Rufiji
HDSS since 2007 [11] and in all facilities after the na-
tional RDT rollout in 2009. Ifakara HDSS has been oper-
ational since 1996 and contains a population of
approximately 99,000 people [12]. Early in 2008, the AC-
CESS project introduced RDT in seven (out of 79)
health facilities in Kilombero and Ulanga districts; four
out of these seven facilities are within the HDSS area
[8]. Although use of RDTs under ACCESS project was
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and guidelines similar to those provided in the rollout
areas for routine case management. These were modified
versions of the generic guides provided by the WHO.
The two areas differ in terms of support supervision and
stock supply for RDTs. In Rufiji, supervision and acquisi-
tion of supplies was to follow routine practices in exist-
ing health system; those under ACCESS project were
assessed by project investigators who were also respon-
sible for replenishing facility supplies of RDTs.
Health facility surveys
Cross-sectional health facility cluster surveys were con-
ducted in March and October 2010. A cluster was
defined as all outpatient consultations in a health facility
conducted in one day during regular working hours. All
government and non-government health facilities that
provide outpatient care to the HDSS population were
included (16 in Rufiji HDSS and 14 in Ifakara HDSS).
Each facility was visited for two to three days with the
goal to collect data on 720 patients per HDSS per year
in order to estimate the proportion of patients with un-
complicated malaria correctly treated with ACT with
10% confidence, assuming 20% of all patients present
with uncomplicated malaria, 75% of patients with un-
complicated malaria are treated with ACT, and a design
effect of 2 for cluster sampling
All outpatients presenting for initial illness consult-
ation on a day of a survey, and who consented to partici-
pate in the survey, were interviewed prior to leaving the
health facility. Using standardized questionnaires devel-
oped in English and translated into Kiswahili, informa-
tion on history of fever, health worker’s diagnoses,
laboratory tests, medications prescribed and counselling
messages were collected. In addition, a reference blood
film for malaria microscopy was collected on every pa-
tient. Patients with severe malaria were excluded from
the survey. Moreover, interviews were carried out with
health workers providing outpatient consultations and
collected information on pre-service training, work ex-
perience, in-service training and receipt of supervision.
Assessment of the level of staffing, availability of diag-
nostics, medications and other medical supplies was
done at the health facility.
Laboratory procedure
Blood films were stained with 10% Giemsa and thick
and thin films were examined by study microscopists at
centralized locations in Rufiji and Ifakara HDSS sites. A
second reading was conducted by a reference laboratory
technician at the Ifakara Health Institute Bagamoyo Re-
search and Training Unit. Parasite densities were calcu-
lated by counting the number of asexual stage parasites
per 200 white blood cells (WBCs) and assuming anaverage of 8,000 WBC per microlitre of blood. A blood
film was considered negative if no parasites were found
after counting 100x high power fields. Blood film results
were made available to the respective health facilities be-
tween five to seven days after the day of survey.
Definitions
National malaria treatment guidelines and clinical infor-
mation from the exit interview were used to determine
when diagnostic testing was indicated, and the same plus
study blood film results to determine when prescription
of ACT was indicated. In the treatment guidelines, mal-
aria diagnostic testing was indicated for patients with fe-
brile illness (history of fever in the last 48 h), and this
was assessed through exit interviews. Malaria was
defined as a patient with febrile illness as determined by
exit interview, and reference blood film positive for mal-
aria parasites. Routine diagnostic testing was defined as
RDT or microscopy ordered by the health worker and
performed at the health facility as part of the health
worker-patient consultation. Correct diagnostic testing
was defined as febrile patient tested with RDT or mi-
croscopy. Over-testing was defined as a non-febrile pa-
tient tested with RDT or microscopy. Correct treatment
was defined as patient with malaria prescribed ACT.
Over-treatment was defined as patient without malaria
prescribed ACT. ACT stock out referred to absence of
all types of AL blister packs.
Data management and analysis
Data were double entered in EPIDATA (version 3.1, EPI-
DATA Association, Odense, Denmark) and analysed
using STATA (version 11.0, STATA Corporation, College
Station, USA) using survey procedures that account for
clustering. An alpha level of 0.05 was used for all signifi-
cance tests. Pregnant women (N= 60) were excluded
from the analysis as quinine rather than ACT is the
recommended treatment of malaria in the first trimester.
Descriptive analysis was performed to derive proportions
for different outcome measures. Logistic regression was
done to identify the impact of diagnostics on prescrip-
tion of AL and overtreatment to patients receiving AL.
Ethical clearance
All components of the INESS platform were reviewed by
the Tanzanian National Institutes of Medical Research
and IHI’s Ethical Review Boards (IHI/IRB/No.A67-2009),
Dar es Salaam, Tanzania.
Results
A total of 1,531 patients were interviewed (742 in Rufiji
HDSS and 789 in Ifakara HDSS) and 1,471 non-
pregnant patients with complete data were included in
the analysis. Almost half of all patients in both areas
Table 1 Characteristics of patients in health facility surveys conducted in pre- and post-RDT implementation
HDSS areas





n/N % (95%CI) n/N %(95%CI)
Female 441/761 58.0 (54.7-61.1) 347/710 48.9 (44.9-52.9) <0.01
Child aged <5 years 352/761 46.3 (41.8-50.8) 349/710 49.2 (44.4-53.9) 0.56
Used insecticide-treated bed net previous night 575/761 75.6 (71.3-79.4) 344/710 48.5 (40.9-56.1) < 0.01
Used anti-malarial prior to health facility visit 37/761 4.9 (3.2-7.3) 20/710 2.8 (1.5-5.3) 0.14
Seen in high transmission season (March 2010) 384/761 50.5 (40.2-60.7) 375/710 52.8 (39.7-65.5) 0.78
Seen in low transmission season (October 2010) 377/761 49.5 (39.3-59.8) 335/710 47.2 (34.5-60.3)
Seen in HF with ACT in stock 326/761 42.8 (30.9-55.7) 666/710 93.8 (86.9-97.2) 0.01
Seen in HF with RDT or BS in stock 248/761 32.6 (21.4-46.1) 527/710 74.2 (61.1-84.1) <0.01
Seen in HF with a RDT in stock 132/761 17.4 (10.6-27.6) 343/710 48.3 (35.2-61.7) <0.01
Seen in a HF with BS in stock 242/761 31.8 (22.0-43.5) 397/710 55.9 (41.9-69.1) 0.28
Fever prevalence 627/761 82.4 (78.3-85.8) 620/710 87.3 (83.3-90.5) 0.06
Uncomplicated malaria prevalence 54/761 7.1 (5.1-9.8) 96/710 13.5 (10.3-17.6) <0.01
High transmission season 36/384 9.4 (6.2-13.9) 72/375 19.2 (14.3-25.3) <0.01
Low transmission season 16/377 4.2 (2.5-7.2) 24/335 7.2 (4.2-12.0) 0.21
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treated bed nets, availability of ACT and diagnostic test-
ing (RDT and microscopy) differed significantly between
the two areas. In particular, more patients in Rufiji
HDSS (post-RDT implementation area) were seen in a
health facility with ACT in stock (93.8%) or with any
diagnostic capacity (RDT or microscopy) (74.2%)
compared to the Ifakara HDSS (pre-RDT implementa-
tion area) where, 42.8% were seen in a health facility
with ACT in stock and 32.6% seen in a health facility
with diagnostic capacity. Moreover, the prevalence of
uncomplicated malaria varied significantly between Rufiji
HDSS (high season 19.2% and low season 7.2%) and
Ifakara HDSS (high season 9.4% and low season 4.2%),




All patients tested by either RDT or microscopy 354/761 4
RDT 132/761 1
Microscopy 242/761 3





Over-testing: Patients without fever tested with either
RDT or microscopy
40/134 2
High season 5/60 8
Low season 35/74 4Results in Table 2 describe the use of RDTs between
the two areas. More patients in the post- RDT area
received a diagnostic test 62.1% (95%CI: 50.3- 72.6) as
compared to a pre-RDT area 46.5% (95%CI: 36.3- 57.1)
(p = 0.05). Use of RDTs was significantly higher in post-
RDT area whereas microscopy use was more common in
the pre-RDT area. Overall correct testing and over-
testing did not differ significantly between two areas.
Table 3 shows ACT prescriptions to malaria patients
as categorized by use of diagnostic tests (RDT and mi-
croscopy) or clinically. In both areas, most RDT-positive
patients received ACT, but only about half microscopy-
positive patients received ACT. RDT-negative patients
were significantly less likely to be treated with ACT in







6.5 (36.3-57.1) 441/710 62.1 (50.3-72.6) 0.05
7.4 (11.0-26.2) 309/710 43.5 (32.4-55.4) < 0.01
1.8 (28.5-35.2) 132/710 18.6 (15.8-21.7) 0.05
0.1 (38.9-61.2) 400/620 64.5 (51.8-75.5) 0.09
9.6 (12.4-29.6) 282/620 45.5 (33.3-58.2) < 0.01
3.5 (29.8-37.3) 118/620 19.0 (16.0-22.3) 0.04
9.9 (16.5-47.9) 41/90 45.6 (32.9-58.8) 0.15
.3 (3.6-18.0) 26/56 46.4 (33.2-60.2) <0.01
7.3 (24.0-71.9) 15/34 44.1 (22.0-68.9) 0.86
Table 3 ACT† prescription according to tests results, and clinical malaria* in pre- and post-RDT implementation areas
Ifakara HDSS (pre- RDT
implementation)
Rufiji HDSS (post- RDT
implementation)
P-value
n/N %(95% CI) n/N %(95% CI)
RDT positive 22/30 73.3 (53.1-87.0) 79/95 83.2 (69.2-91.6) 0.32
RDT negative 28/104 26.9 (16.4-40.9) 17/217 7.8 (4.7-12.7) <0.01
Microscopy positive 62/110 56.4 (41.5-70.1) 15/36 41.7 (22.1-64.3) 0.28
Microscopy negative 7/135 5.2 (2.1-12.1) 5/96 5.2 (2.3-11.6) 0.99
Clinical diagnosis of malaria and
no diagnostic test performed
165/313 52.7 (42.9-62.4) 99/220 45.0 (34.3-56.2) 0.33
No clinical diagnosis of malaria and
no diagnostic test performed
7/94 7.5 (2.9-15.8) 2/49 4.1 (1.1-14.4) 0.45
* Clinical diagnosis of malaria based on presence of fever in patients who did not receive a malaria diagnostic test †=Artemether lumefantrine.
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ing ACT based on clinical diagnosis alone did not differ
between the two sites. In the multivariate analysis
(Table 4), the odds of febrile patients receiving ACT
were highest with clinical diagnosis (adjusted OR 95%CI:
2.24(1.37-3.67).
Overall ACT use and correct treatment of malaria
were about similar in the two areas, except during high
transmission season (Table 5) but over-treatment of
non-malaria patients with ACT was significantly higher
in the pre-RDT area (39.1%; 95%CI 31.0-47.8) compared
to the post-RDT area (24.7%; 95%CI 18.4-32.2), adjusted
OR(95%CI) 0.57 (0.36-0.89); Table 6. Seasonal differ-
ences were noted in malaria prevalence (Table 1), testing
rate (Table 2), correct treatment and over-treatment
(Table 5).
Discussion
Parasitological confirmation of all malaria diagnoses is
recommended by WHO and there is increasing evidence
supporting the use of RDTs for clinical management ofTable 4 Multivariate analysis of ACT† prescription according
patients in pre- and post-RDT implementation areas




Clinical diagnosis 1.29 0.87-1.91
Season
High season Ref
Low season 0.64 0.43-0.97
Site
Ifakara HDSS (pre-mRDT) Ref
Rufiji HDSS (post-mRDT) 0.74 0.49-1.12
¥: adjusted for season and site.
†: adjusted for type of diagnosis and site.
{: adjusted for type of diagnosis and season.fever and malaria cases [13-15]. Many of these findings
are based on operational research that assessed perform-
ance and accuracy of RDT use in clinical care as part of
a pilot or research projects. This study evaluated the im-
plementation of RDTs for routine use in the Tanzanian
health system, under “real world” conditions. Most im-
portantly, in the post-RDT implementation area correct
treatment of malaria remained high (80.9%) and over-
treatment of non-malaria patients was low (24.7%). This
suggests that the routine use of RDTs might improve
malaria case management.
Tanzania began and phased introduction of RDTs for
routine malaria case management in 2008 and plans to
achieve nationwide coverage by 2011 [National guideline
for the use of rapid malaria diagnostic tests in Tanzania,
2007, National Malaria Control Programme, Dar es Sa-
laam, Tanzania: unpublished]. The scaling up of health
interventions is a complex undertaking and simply in-
creasing coverage might not translate into an impact on
the larger population [16,17]. By comparing the post-RDT
implementation area to the pre-RDT implementation area,to tests results, and clinical malaria* for all febrile
p-value Adjusted Odd ratio 95%CI p-value
0.02 0.61¥ 0.38-1.01 0.054
0.21 1.30¥ 0.87-1.95 0.201
0.036 0.67† 0.45-1.00 0.048
0.15 0.72{ 0.48-1.10 0.127
Table 5 Prescription of ACT for all patients in post- and pre-RDT implementation areas with ACT in stock at health
facility





n/N %(95% CI) n/N %(95% CI)
All patients treated with ACT (overall) 241/587 41.1 (33.4-49.2) 217/666 32.6 (26.5-39.4) 0.10
High transmission season (March 2010) 155/332 46.7 (38.9-54.6) 119/349 34.1 (27.9-40.9) 0.02
Low transmission season (October 2010) 86/255 33.7 (22.6-47.0) 98/317 30.9 (20.7-43.4) 0.74
Correct treatment: Patients with
uncomplicated malaria treated with ACT (overall)
26/37 70.3 (54.7-82.2) 76/94 80.9 (68.2-89.3) 0.22
High transmission season (March 2010) 14/24 58.3 (39.4-75.1) 61/71 85.9 (72.0-93.6) 0.01
Low transmission season (October 2010) 12/13 92.3 (54.2-99.2) 15/23 65.2 (36.2-86.1) 0.11
Over treatment: Patients without
uncomplicated malaria treated with ACT (overall)
215/550 39.1 (31.0-47.8) 141/572 24.7 (18.4-32.2) 0.01
High transmission season (March 2010) 141/308 45.8 (37.2-54.6) 58/278 20.9 (14.7-28.8) <0.01
Low transmission season (October 2010) 74/242 30.6 (19.6-44.3) 83/294 28.2 (18.2-41.1) 0.78
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can be assessed. First, the post-RDT implementation area
had much higher availability of malaria diagnostic testing
capacity; 74% of patients were seen in a health facility that
had either RDTs or microscopy available compared to
32.6% of patients seen on the pre-RDT implementation
area. However, availability of diagnostics alone does not
improve malaria case management. In particular, more
patients were tested for malaria in the post-RDT imple-
mentation area (62.1%) than the pre-RDT implementation
area (46.5%), and more patients were correctly tested.
Despite the improvement seen in proportion of febrile
patients receiving a test, this achievement is far from op-
timal. The reason could be associated with the much too
frequent stock out of medical products affecting the
Tanzania health system, including timely in-availability
of testing materials/devices. However, results show that
over-testing in post implementation area is also high.
Over-testing may be associated with wasted resources asTable 6 Multivariate description of ACT over-treatment for al




Clinical diagnosis 2.54 1.56-4.12
Season
High season Ref
Low season 0.89 0.57-1.38
Site
Ifakara HDSS(pre-mRDT) Ref
Rufiji HDSS(post-mRDT) 0.50 0.32-0.8
¥: adjusted for season and site.
†: adjusted for type of diagnosis and site.
{: adjusted for type of diagnosis and season.patients who do not meet clinical criteria for malaria
diagnostic testing are tested. Although we did not assess
reasons for over-testing, one may think that the problem
may be contributed by lower understanding of case se-
lection for the test, probably resulting from lack of ex-
perience in using the tests, unclear guideline, supportive
supervision not focusing on the topic or even patient
pressure to get tested. Post-implementation care quality
improvement efforts should focus on ensuring that only
persons who have clinical signs and symptoms of mal-
aria such as a history of fever are tested.
Another important consideration for RDT imple-
mentation is assuring the diagnostic test perform-
ance. In this study, sensitivity and specificity of RDTs
in the post-implementation area was adequate (>85%;
see Additional file 1). The continued monitoring of RDT
performance post-implementation is critical as poor mal-
aria microscopy performance has been documented
throughout sub-Saharan Africa. For the time being, RDTsl patients in post- and pre-RDT implementation areas
p-value Adjusted Odd ratio 95%CI p-value
0.48 1.05¥ 0.60-1.84 0.856
0.00 2.24¥ 1.37-3.67 0.001
0.587 0.82 † 0.54-1.23 0.328
0.004 0.57{ 0.36-0.89 0.014
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microscopy and might be critical in improving the overall
quality of malaria diagnostic capacity in routine settings.
In addition, this study suggests that adherence to RDT
results is reasonably high with 83.2% of RDT-positive
patients receiving ACT and only 7.8% of RDT-negative
patients receiving ACT. Adherence to diagnostic test
results is critical if the implementation of RDTs is
expected to reduce over-treatment. Unlike previous
studies, this study suggests that health workers do ad-
here to RDT results, even after routine implementation
of RDTs. In addition, findings from this study also con-
firm reports from previous studies in Tanzania, that
RDT introduction can lower anti-malarial drug con-
sumption [13] and may help reduce the problem of anti-
malarial drug stock-outs. This may imply that once a
policy of malaria diagnostic confirmation expands to the
entire country, the availability of ACT in the Tanzanian
health sector might be significantly improved.
This study showed that only about a third of fever
patients actually received ACT in the post RDT imple-
mentation area, despite the fact that most of the patients
(94%) were seen in a facility with ACT in stock. As the
use of the rapid tests increase once introduced, health
workers’ performance is likely to improve since there
will be an added tool in the line of care that provides
more job and client satisfaction [18]. Some community
studies in Tanzania and elsewhere indicate that commu-
nity members are willing to receive and pay for a labora-
tory test prior to malaria treatment [19]. Moreover,
some studies reported that clients’ demand for a malaria
confirmatory test before treatment [20] and having a
malaria test increased patient satisfaction with clinical
care provided [18,19].
Rapid tests seemed to be performing better than mi-
croscopy. It is important to become conscious of the
possibility for over-estimation of positivity rate that
might result from use of RDTs. In particular, this is likely
to be a problem with the use of histidine rich protein-2
based RDT devices for detecting Plasmodium falcip-
arum infection, as they may continue to test positive
weeks after parasite clearance. In this case, training on
RDTs should stress the need for assessing other disease
conditions despite a positive test for malaria, and referral
to higher level of care for a microscopic examination of
malaria. This is particularly important for providing
quality care of malaria patient in the changing malaria
transmission patterns, with a downward trend observed
in many malaria endemic countries. It as well, supports
present efforts to obtain accurate information about the
disease burden in the population.
There are several limitations to this evaluation. First,
this survey was carried out in established health facilities
where both the providers and patients were aware of thepresence of the study team. This may have inadvertently
influenced prescription behaviour of the providers. Care
was taken to use field interviewers who were local resi-
dents of the survey area. Response bias was minimized
by using survey tools that recorded what was done on
the survey day without longer recall periods, except for
provider’s experience and training. Secondly, the survey
was limited to health facilities within the HDSS areas
and since the HDSS conducts many health interventions
and research studies, this may render the population
more health conscious than the general population.
Third, the presence of RDTs in the pre-RDT implemen-
tation area and some RDT stock-outs in the post-RDT
implementation area, may have underestimated the true
impact of rolling out RDTs. Methodologically, a ‘before
and after’ design would have provided a better measure
of RDT impact in case management, but the purpose of
this evaluation was to assess performance of health care
system with all the bottlenecks associated with it such as
stock outs of medicines, diagnostics and other medical
products. In addition, prescription practices may differ
from one area of practice to another due to common
experiences and governing principles. This may affect
the true measure of impact of RDT implementation be-
tween the study areas. Lastly, ACT stock out was an-
other limitation that might have affected the true impact
of the programme.
Conclusions
In conclusion, the implementation of RDTs increased
use of RDTs for parasitological confirmation and
reduced over-treatment with ACT during high malaria
transmission season in one area in Tanzania. Continued
monitoring of the national RDT rollout will be needed
to assess whether these changes in case management
practices will be replicated in other areas and sustained
over time. Additional measure such as refresher train-
ings, closer supportive supervisions, etc., may be needed
to improve ACT targeting during low transmission sea-
sons. The need to extend parasitological confirmation of
malaria in the context of integrated community case
management is becoming apparent and needs to be
addressed.
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